Downingtown, PA, United States of America

Jill M Giles-Komar

This inventor holds 56 USPTO granted patents and 12 published patent applications, plus 6 CIPO patents and 16 EPO patents, primarily in Monoclonal Antibodies (CPC class C07K). Top assignees: Janssen Biotech, Inc., Centocor, Inc., Centocor Ortho Biotech Inc.. Active years: 2005-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jill M Giles-Komar. Retrieved from https://idiyas.com/inventor/jill-m-giles-komar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 56 (Patent Applications = 12)

% Patents Active = 57.1

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 16 (Patent Applications = 13)

Average Co-Inventor Count = 5.3

ph-index = 18

Forward Citations = 1,196(Granted Patents)

Forward Citations (Not Self Cited) = 1,176(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Dowingtown, PA (US) (2010)
Berwyn, PA (US) (2010)
Downington, PA (US) (2012)
Radnor, PA (US) (2012 - 2013)
Spring House, PA (US) (2014 - 2018)
Downingtown, PA (US) (2005 - 2023)

Company Filing History:

27 out of 433

Janssen Biotech, Inc.

Centocor Ortho Biotech Inc.

patents

4. 2 out of 834,513

Other

patents

Years Active: 2005-2024

Loading Chart...

Areas of Expertise:

Anti-IL-23 Antibodies

Anti-TNF Antibodies

Anti-IL-12 Antibodies

Anti-IL-6 Antibodies

Anti-CD3 Antibodies

Anti-Integrin Antibodies

Engineered Antibodies

Hybridoma Fusion

Nucleic Acids

Toll Like Receptor Antagonists

Compositions

Methods

56 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12161716 - Anti-IL-23 antibodies, compositions, methods and uses (2024-12-10),

2. 11603405 - Anti-CD3 antibodies and uses thereof (2023-03-14),

3. 11185584 - Anti-IL-23 antibodies, compositions, methods and uses (2021-11-30),

4. 11078267 - Method for treating lupus by administering an anti-IL-12 antibody (2021-08-03),

5. 10576150 - Anti-IL-23 antibodies (2020-03-03),

6. 10519231 - Method for treating lupus by administering an anti-IL-12 antibody (2019-12-31),

7. 10272152 - Anti-IL-23 antibodies, compositions, methods and uses (2019-04-30),

8. 10259867 - Method for treating lupus by administering an anti-IL-12 antibody (2019-04-16),

9. 9862766 - Method of treating lupus by administering an anti-IL-12 antibody (2018-01-09),

10. 9828424 - Anti-TNF antibodies, compositions, methods and uses (2017-11-28),

11. 9714287 - Anti-IL-23 antibody compositions (2017-07-25),

12. 9676848 - Anti-IL-12 antibodies and compositions (2017-06-13),

13. 9605067 - Nucleic acids encoding anti-IL-12 antibody (2017-03-28),

14. 9505837 - Anti-IL-23 antibodies (2016-11-29),

15. 9428579 - Method of treating Crohn's disease by administering an anti-IL-12 antibody (2016-08-30),

Title: **Jill M Giles-Komar: Innovator in Antibody Therapeutics**

Introduction

Jill M Giles-Komar, based in Downingtown, Pennsylvania, has made significant contributions to the field of biotechnology, particularly in the development of antibody therapies. With an impressive portfolio of 56 patents, Giles-Komar has been at the forefront of innovations that hold promise for the treatment of various diseases.

Latest Patents

Among her recent innovations, Giles-Komar has developed patents related to anti-IL-23 antibodies, which include isolated nucleic acids that encode these antibodies, as well as methods for their production and application in diagnostic and therapeutic settings. Additionally, her patent portfolio encompasses anti-CD3 antibodies and their uses, focusing on antibodies that specifically bind to CD3, PSMA, IL1RAP, CD33, and TMEFF2. These advancements represent cutting-edge approaches in immunotherapy, providing new avenues for treatment and diagnosis.

Career Highlights

Throughout her career, Jill M Giles-Komar has made impactful contributions while working with renowned companies in the biotechnology sector such as Janssen Biotech, Inc. and Centocor, Inc. Her work has not only resulted in a substantial number of patents but has also propelled forward the understanding and application of antibody-based therapies.

Collaborations

Giles-Komar has collaborated with prominent colleagues, including David M Knight and Bernard Scallon. These partnerships have enhanced her research capabilities and contributed to the successful development of innovative therapeutic strategies.

Conclusion

Jill M Giles-Komar stands out as an influential inventor in the realm of antibody therapeutics. Her extensive patent portfolio showcases her commitment to advancing medical science and improving patient outcomes through innovative therapies. Her work continues to inspire future developments in biotechnology, reflecting the ongoing need for innovation in healthcare solutions.

Profile summary based on public USPTO records.